SK CAPITAL PARTNERS

SK CAPITAL PARTNERS is a Series C+ and buyout fund in the US and Europe writing $100M–$500M checks into Healthcare, specialty-materials, ingredients, life-sciences, biotechnology, distributors-wholesale, buildings-property, food-products, medical-supplies and chemicals-materials.

Stages: Series C+, buyout
Sectors: Healthcare, specialty-materials, ingredients, life-sciences, biotechnology, distributors-wholesale, buildings-property, food-products, medical-supplies, chemicals-materials
Check size: $100M–$500M
Invests in: US-wide, Europe
Round role: Leads rounds
Actively investing: Yes
Founded: 2007
Assets under management: $8.36B

Thesis

SK Capital Partners is a global private investment firm founded in 2007, specializing in the specialty materials, ingredients, and life sciences sectors. Their investment strategy focuses on acquiring and enhancing businesses through control-oriented, transformative investments, utilizing deep industry expertise, operational knowledge, and extensive networks. They operate with two primary programs: the "Flagship" strategy for upper mid-sized and larger companies, and the "Catalyst" funds for smaller and mid-sized companies. The firm's geographic scope is global, with a significant focus on North America and Europe. As of early 2026, SK Capital manages approximately $8.36 billion in AUM, having raised $2.1 billion for Fund V in 2019, $2.95 billion for Fund VI in April 2024, and an $800 million "SKCP Catalyst Fund II" in 2023. They typically invest $100 to $200 million of equity in transactions valued up to $500 million, targeting companies with revenues between $50 to $500 million and at least $100 million in EBITDA.

Common questions

Does SK CAPITAL PARTNERS invest at the Series C+ stage?

Yes. SK CAPITAL PARTNERS lists Series C+ and buyout among the stages it invests in.

What check size does SK CAPITAL PARTNERS write?

SK CAPITAL PARTNERS writes $100M–$500M checks.

Where does SK CAPITAL PARTNERS invest?

SK CAPITAL PARTNERS invests in the US and Europe.